Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06273891
Other study ID # INOVA-2023-58
Secondary ID 23-08-WC-0198
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 8, 2024
Est. completion date October 1, 2025

Study information

Verified date June 2024
Source Inova Fairfax Hospital
Contact Antonio Saad, MD, MBA
Phone 7037766040
Email antonio.saad@inova.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. Participants diagnosed with PPROM will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. Studying these two drugs will help decide the best care for future patients with PPROM.


Description:

Preterm pre-labor rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-fourth to one-third of preterm births. PPROM is associated with significant maternal and neonatal morbidities, including chorioamnionitis, endometritis, neonatal sepsis, prematurity-related pathologies. In the absence of labor or indication for immediate delivery, patients who present at less than 34 weeks gestational age are treated with antibiotics to prolong pregnancy until 34 weeks when the risks of prematurity are decreased. Based on randomized trials, both the American College of Obstetrics and Gynecology (ACOG) and the Society of Maternal Fetal Medicine (SMFM) recommend IV ampicillin and IV erythromycin for 2 days, followed by an oral regimen of amoxicillin and erythromycin for 5 days. Due to the recent limited availability of erythromycin, azithromycin has been used a substitute. There have been observational studies showing no difference in duration of pregnancy between azithromycin and erythromycin, however no randomized controlled trial has been carried out to our knowledge. This study performs a cluster randomized controlled trial to examine the efficacy of azithromycin versus erythromycin as a component of the "latency antibiotics" used to prolong pregnancy in PPROM patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date October 1, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Pregnancy at 22 weeks 0 days to 32 weeks 6 days of gestation. - Rupture of membranes confirmed by biochemical testing. - Membrane rupture within the past 36 hours. - Cervical dilation 3 cm or less and 4 or fewer contractions within 60-minutes at the time of admission. - Age =18 and <50 years. Exclusion Criteria: - Non-reassuring fetal heart tracing, vaginal bleeding, chorioamnionitis or any indication for delivery at admission. - Allergy to penicillin, erythromycin, or azithromycin. - Multiple gestations.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Erythromycin
Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days
Azithromycin
Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days

Locations

Country Name City State
United States Inova Fairfax Medical Campus Falls Church Virginia
United States Eastern Viriginia Medical School Norfolk Virginia

Sponsors (2)

Lead Sponsor Collaborator
Inova Fairfax Hospital Eastern Virginia Medical School

Country where clinical trial is conducted

United States, 

References & Publications (3)

Drassinower D, Friedman AM, Obican SG, Levin H, Gyamfi-Bannerman C. Prolonged latency of preterm prelabour rupture of membranes and neurodevelopmental outcomes: a secondary analysis. BJOG. 2016 Sep;123(10):1629-35. doi: 10.1111/1471-0528.14133. Epub 2016 May 31. — View Citation

Navathe R, Schoen CN, Heidari P, Bachilova S, Ward A, Tepper J, Visintainer P, Hoffman MK, Smith S, Berghella V, Roman A. Azithromycin vs erythromycin for the management of preterm premature rupture of membranes. Am J Obstet Gynecol. 2019 Aug;221(2):144.e1-144.e8. doi: 10.1016/j.ajog.2019.03.009. Epub 2019 Mar 20. — View Citation

Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217. Obstet Gynecol. 2020 Mar;135(3):e80-e97. doi: 10.1097/AOG.0000000000003700. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Latency period Time from PPROM to delivery between the two treatments Number of days from PPROM to delivery, assessed up to 105 days
See also
  Status Clinical Trial Phase
Completed NCT04100252 - The Impact of Amniotic Fluid Index (AFI) on Maternal and Perinatal Outcomes in Pregnant Women With Preterm Premature Rupture of Membranes
Recruiting NCT04478942 - PROMMO Trial: Oral Misoprostol vs IV Oxytocin Early Phase 1
Recruiting NCT02819570 - Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes Phase 4
Withdrawn NCT03172858 - Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices N/A
Not yet recruiting NCT05134688 - Magnesium Sulphate in Premature Rupture of Membranes Early Phase 1
Not yet recruiting NCT03689062 - Premature Rupture of Membranes at 34 to 37 Weeks' Gestation N/A
Recruiting NCT04237142 - Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL) N/A
Recruiting NCT04558996 - Spanish Registry of Pregnant Women With COVID-19
Recruiting NCT04632017 - Computerized Cardiotocography Monitoring of Fetuses With pPROM
Recruiting NCT03607929 - HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor N/A
Completed NCT03491826 - Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
Enrolling by invitation NCT04451109 - Dilapan-S®: A Multicenter US E-registry
Recruiting NCT04143685 - Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes N/A
Completed NCT03251898 - Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
Completed NCT03106311 - The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes N/A